Well-Differentiated Systemic Mastocytosis vs Chronic Mast Cell Leukemia
The panel of experts discuss the clinical differences between well-differentiated systemic mastocytosis and chronic mast cell leukemia.
Case 4: Treatment and Management Considerations in MCL
The panel of experts in SM discuss the diagnosis and treatment of a 68-year-old female with mast cell leukemia.
Case 3: Indolent Systemic Mastocytosis
Dan DeAngelo, MD, PhD, presents the case of a patient with indolent systemic mastocytosis and urticaria pigmentosa.
Avapritinib: Approval and Clinical Practice Implications
A panel of experts share their reactions to the approval of avapritinib and discuss the clinical implications.
Case 2: Treatment and Management Considerations for SM
The panel of experts in SM discuss the diagnosis and management of a 46-year-old woman with systemic mastocytosis.
Case 1: Treatment Algorithm and Supportive Care Recommendations
Patricia Lugar, MD, MS, shares treatment algorithm and supportive care recommendations for a 75-year-old man with systemic mastocytosis.
Case 1: Treatment and Management Considerations
The panel of experts in SM discuss the diagnosis and management of a 75-year-old man with systemic mastocytosis.
Case 1: 75-Year-Old Man With SM
Dan DeAngelo, MD, PhD, presents the case of a 75-year-old man with systemic mastocytosis and reviews WHO diagnostic criteria.
Considerations in SM: Hereditary Alpha Tryptasemia
Prithviraj Bose, MD, and Patricia Lugar, MD, MS, discuss the considerations and testing options for hereditary alpha tryptasemia in patients with systemic mastocytosis.
Considerations in Mast Cell Disorders
The panel of experts highlights the importance of assessing symptomology and clinical characteristics in mast cell disorders.
Systemic Mastocytosis: Epidemiology and Diagnostic Criteria
Experts in the field of mast cell disorders discuss the epidemiology and diagnostic criteria of systemic mastocytosis.
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
2 Commerce Drive Cranbury, NJ 08512